ArticlePLoS neglected tropical diseases2022
Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao.
Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Burden of Chikungunya Fever and Its Economic and Social Impacts Worldwide: A Systematic Review.Tropical medicine & international health : TM & IH · 2025Pooled it
- Assessing chikungunya's economic burden and impact on health-related quality of life: Two systematic literature reviews.PLoS neglected tropical diseases · 2025Pooled it
- A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.Journal of travel medicine · 2024Trial
- Acute-phase clinical profile and quality of life in patients with chikungunya during the 2025 outbreak in Bangladesh: A facility-based cross-sectional study.PLoS neglected tropical diseases · 2026Article
- Limited tissue persistence confirms attenuation of live-attenuated chikungunya vaccine VLA1553 in non-human primates.NPJ vaccines · 2026Article
- Unveiling Clinical Phenotypes in Chronic Chikungunya Disease: Insights from a Brazilian Observational Study.Tropical medicine and infectious disease · 2026Article
- Article
- Evaluating chikungunya outbreak size and emergency vaccination strategies in Miami: an exploratory modeling study.BMC public health · 2025Article
- Chikungunya virus infection in the skin: histopathology and cutaneous immunological response.Frontiers in microbiology · 2025Article
- Strategic vaccination responses to Chikungunya outbreaks in Rome: Insights from a dynamic transmission model.PLoS neglected tropical diseases · 2024Article
- A sequential study of Chikungunya fever cases notified in the urban setup of India.Journal of family medicine and primary care · 2024Article
- From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine.Journal of travel medicine · 2024Review
- The risk and risk factors of chikungunya virus infection and rheumatological sequelae in a cohort of U.S. Military Health System beneficiaries: Implications for the vaccine era.PLoS neglected tropical diseases · 2024Article
- Adaptive coping strategies among individuals living with long-term chikungunya disease: a qualitative study in Curaçao.BMJ open · 2024Article
- "It's very saddening, you keep on wondering when the symptoms will be over": A qualitative study exploring the long-term chikungunya disease impact on daily life and well-being, 6 years after disease onset.PLoS neglected tropical diseases · 2023Article
- "What will the doctor give me, the same painkiller?": a qualitative study exploring health-care seeking and symptoms self-management among patients for the treatment of long-term chikungunya disease, in Curaçao.BMC health services research · 2023Article
- The Chikungunya anxiety scale (CHIKAS): Development, validation, and relationship between its items and illness-related factors.Industrial psychiatry journal · 2023Article
- Madariaga and Venezuelan equine encephalitis virus seroprevalence in rodent enzootic hosts in Eastern and Western Panama.bioRxiv : the preprint server for biology · 2023Article
- Epidemiology and Economic Burden of Chikungunya: A Systematic Literature Review.Tropical medicine and infectious disease · 2023Review
- Correction: Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao.PLoS neglected tropical diseases · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLittle is known about the persistence and impact of non-rheumatic symptoms after acute chikungunya disease. We have studied the clinical presentation and long-term impact of rheumatic and non-rheumatic symptoms on health related quality of life (QoL) 2.5 years after disease onset. Additionally, the validity of the Curaçao Long-Term Chikungunya Sequelae (CLTCS) score in classifying disease severity over time was evaluated. METHODOLOGY/PRINCIPAL
findingsThis prospective cohort study followed 248 chikungunya patients. Symptoms and SF-36 QoL were evaluated during baseline and follow-up at 2.5 years using questionnaires. Chikungunya disease status was classified using the CLTCS-score. At 2.5 years after disease onset patients were classified as being recovered (43%), mildly (35%) or highly (22%) affected. In comparison to mildly affected, highly affected patients reported the highest prevalence of ongoing rheumatic and non-rheumatic/psychological symptoms, with increased prevalence of arthralgia in the lower extremities (p = .01) and fatigue (p = .049) over time, and higher pain intensity (p < .001). Compared to mildly affected, being highly affected was associated with weakness in the lower extremities (OR: 1.90; CI: 1.29-2.80, p = .001) and worsened physical and mental QoL impairment.
conclusionsPatients are both physically and psychologically affected by rheumatic and non-rheumatic symptoms of long-term chikungunya disease. The CLTCS-score is an easy to use instrument for classifying long-term chikungunya disease severity and impact and can facilitate health care providers in identifying highly affected patients who are prone to develop severe QoL impairment. Highly affected patients are recommended to be treated in a multidisciplinary setting to improve physical and psychological functioning, and QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.